- Other genetic FGF/FGFR pathway aberrations may be acceptable should such genetic changes be observed to emerge and require approval per the lead investigator for enrollment (e.g. fibroblast growth factor (FGF) amplification); should one genetic aberration be overrepresented in one or both of the arms the lead investigator (Dr. Seiwert) may decide to restrict enrollment of such patients; a notification/memo will be sent out to all investigators should such a restriction on enrollment be implemented (see inclusion criteria); for example, if more than 5 pts with FGFR1 amplification are enrolled further enrollment of FGFR1 amplified patiens will be put on hold, or if FGFR translocations are under-represented enrollment may be focused on this aberration